ClinicalTrials.gg
RecruitingNCT06319911Updated May 7, 2024

AETOS Shoulder System

An observational study in Shoulder Osteoarthritis and Shoulder Arthritis, sponsored by Smith & Nephew, Inc.. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-07.

Sponsored by Smith & Nephew, Inc. · Observational

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
220
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 41 studies in Osteoarthritis by Smith & Nephew, Inc. — 2 open to participants now, 7 under way, none of them phase 3. Osteoarthritis · Smith & Nephew, Inc..

Planned enrollment
4th of 24
220 · median 131
Started
2024
with 1 other
Observational
24 of 41
2 open now
Registered
39th of 41
by date

Among the 41 studies in Osteoarthritis by Smith & Nephew, Inc., this one is the 4th largest by planned enrollment of the 24 observational ones that give a count, is one of 2 that started in 2024, is one of 24 observational ones, and was the 39th registered.

Osteoarthritis

2,977 studies on the registry are indexed under Osteoarthritis; 437 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

2 of the 41 studies in Osteoarthritis by Smith & Nephew, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 284 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Osteoarthritis by Smith & Nephew, Inc., or all of them as a file.
02

Study summary

The goal of this study is to confirm the safety and performance of the AETOS Shoulder System for USA adoption. This is a prospective, open, adaptive, non-comparative, multi-centre investigation enrolling a maximum of 220 subjects in 2 cohorts (anatomic and reverse) at up to 15 sites. No intra-study comparator group will be included, and there will be no randomization

Read the detailed description

This study will confirm the safety and performance of the AETOS Shoulder System in anatomic and reverse TSA. Revisions will not be enrolled into this study.

The AETOS Shoulder System is manufactured by Smith \& Nephew, Inc., 1450 Brooks Road Memphis, Tennessee 38116 USA, and has been 510k Cleared as of 07Jun2023; therefore, it is considered a post-market product and will be procured through normal commercial channels in the USA. The humeral stem is designed to be used for both Total Shoulder Arthroplasty (TSA) and reverse shoulder arthroplasty procedures. The humeral stems are designed with fins and a porous plasma coating to provide fixation within the proximal humeral metaphysis.

03

Conditions studied

  • Shoulder Osteoarthritis
  • Shoulder Arthritis

Browse trials for

Keywords

  • Shoulder
  • arthroplasty
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Males and females who are at least 18 years of age at the time of consent, are skeletally mature, and are indicated for primary anatomic or primary reverse will be enrolled in the study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet all the following criteria to be included in the study:

  1. Patient is at least 18 years of age at the time of consent and skeletally mature.
  2. Patient is undergoing a primary elective anatomic or reverse shoulder replacement surgery for one of the following indications:

    • Rheumatoid arthritis, and/or
    • Traumatic arthritis (Post Traumatic arthritis), and/or
    • Non-inflammatory degenerative joint disease, and/or
    • Correction of functional deformity.
  3. Patient is willing and able to accommodate all study-related procedures and visits detailed in the protocol \& cooperate in the standard of care post-operative therapy.
  4. Patient is geographically stable and willing to return to the study site for all follow-up visits.
  5. Patient has been adequately informed of risks and requirements of the study and is willing and able to provide for participation.

Exclusion criteria

-

Exclusion Criteria:

Patients who meet any of the following criteria will not qualify for participation in the trial:

  1. Patient has a to AETOS.
  2. Patient is undergoing a revision shoulder replacement surgery including total or partial arthroplasty.
  3. Patient is indicated for a Hemiarthroplasty.
  4. Patient has traumatic injury or a fracture.
  5. Patient has uncontrolled diabetes with a of 7.5 or greater.
  6. Patient has comorbidities/conditions that preclude proper healing/fixation of the implant.
  7. Patient has poor quality or insufficient bone stock to support the implant.
  8. Patient has poor bone quality where there could be considerable migration of the implant and/or a chance of fracture.
  9. Patient has rapid joint destruction, marked bone loss or bone resorption (e.g., severe osteoporosis).
  10. Patient has osteomalacia.
  11. Patient has muscular, neurologic, or vascular deficiencies that may compromise the outcome of the shoulder replacement surgery.
  12. Patient has a known sensitivity, allergic reaction, and/or known allergies to one or more of the implanted materials.
  13. Patient has a distant foci of infection which may spread to the implant site, active local or systemic infection, sepsis, or osteomyelitis.
  14. Patient has an elevation of sedimentation rate, elevation of WBC count, or marked shift in WBC differential count unexplained by other disease.
  15. If reverse shoulder arthroplasty, patient has a non-functional deltoid or external rotator muscles.
  16. If reverse shoulder arthroplasty, patient has a significant injury to the upper brachial plexus.
  17. If reverse shoulder arthroplasty, patient has paralysis of the axillary nerve.
  18. Patient is uncooperative, has a neurologic disorder and is not capable of following directions, or is a vulnerable subject per ISO 14155 (i.e., individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response).
  19. Patient is pregnant or plans to become pregnant during the follow-up period.
  20. Patient has a (BMI) of >35kg/m2 or a BMI that may compromise the outcome of the shoulder replacement surgery.
  21. Patient has anticipated activities which would impose high stresses on the implant and its fixation or has a high likelihood of a fall.
  22. Patient is a known smoker, vaper, alcohol abuser, or drug abuser within 180 days of consent.
  23. Patient has participated previously in this clinical trial and was withdrawn.
  24. Patient is participating in another device or drug trial or observational competitive study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
220 participants (estimated)
Patient registry
No

Groups and cohorts

  • Primary Anatomic

    Those subjects who have the AETOS implanted in the Primary Anatomic configuration

    Device: AETOS

  • Primary reverse

    Those subjects who have AETOS implanted in the Reverse configuration

    Device: AETOS

Interventions

  • DeviceAETOS

    The AETOS Shoulder System will be implanted into the right or left shoulder in the anatomic or reverse configuration

06

What researchers measure

Primary outcomes

  1. Implant Survivorship

    Implant survivorship at 2 years post operatively defined as absence of device removal or revision of any component

    Time frame: 2 years

Secondary outcomes

  1. Implant Survivorship at 6 months, 1 year, 3.5 years and 5 years

    Implant Survivorship at 6 months, 1 year, 3.5 years, and 5 years defined as absence of device removal or revision of any component

    Time frame: 6 months, 1 year, 3.5 years, and 5 years

  2. Radiographic Assessment - Glenoid Migration/Subsidence

    Glenoid Component Migration / Subsidence collected post-surgery at day 0, 1 year, 2 years, and 5 years will be graded in accordance with the following definitions: 0. Absent: No evidence of glenoid component displacement ≥ 5 mm relative to the native bone stock. 1. Present: Presence of glenoid component displacement ≥ 5 mm relative to the native bone stock.

    Time frame: Day 0, 1 year, 2 years, and 5 years

  3. Radiographic Assessment - Glenoid Radiolucency

    Glenoid Component Radiolucency - antero-posterior (AP) collected post-surgery at day 0, 1 year, 2 years, and 5 years will be graded in accordance with the following definitions: 0. Absent: No evidence of radiolucency \> 2 mm in width along the bone-implant / bone-cement interface in any zone. 1. Present: Presence of radiolucency \> 2 mm in width along the bone-implant / bone-cement interface in one or more zones.

    Time frame: Day 0, 1 year, 2 years, and 5 years

  4. Radiographic Assessment - Humeral Radiolucency

    Humeral Component Radiolucency - AP collected post-surgery at day 0, 1 year, 2 years, and 5 years will be graded in accordance with the following definitions: 0. Absent: No evidence of radiolucency \> 2 mm in width along the bone-implant interface in any zone. 1. Present: Presence of radiolucency \> 2 mm in width along the bone-implant interface in one or more zones.

    Time frame: Day 0, 1 year, 2 years, and 5 years

  5. Radiographic Assessment - Humeral Migration/Subsidence

    Humeral Component Migration / Subsidence collected post-surgery at day 0, 1 year, 2 years, and 5 years will be graded in accordance with the following definitions: 0. Absent: No evidence of a change in position of the humeral component relative to the native bone stock ≥ 5 mm. 1. Present: Presence of a change in position of the humeral component relative to the native bone stock ≥ 5 mm

    Time frame: Day 0, 1 year, 2 years, and 5 years

  6. Radiographic Assessment - Humeral Head Centeredness

    Humeral Head Centeredness collected post-surgery at day 0, 1 year, 2 years, and 5 years will be calculated using the method described by Iannotti and Norris from the axillary view

    Time frame: Day 0, 1 year, 2 years, and 5 years

  7. Radiographic Assessment - Bone Remodeling

    Bone Remodeling of the humerus collected post-surgery at day 0, 1 year, 2 years, and 5 years will be graded in accordance with the following definitions by Schnetzke et al.: 0. Absent: No evidence of humerus bone remodeling. 1. Present: Presence of one or more features of humerus bone remodeling. * 1. Condensation Lines: Presence of condensation lines around the tip of the stem. * 2. Cortical Thinning: Presence of cortical thinning and osteopenia. * 3. Spot Welds: Presence of spot welds. * 4. Other: Other feature not listed above.

    Time frame: Day 0, 1 year, 2 years, and 5 years

  8. Radiographic Assessment - Glenohumeral Subluxation

    Glenohumeral Subluxation collected post-surgery at day 0, 1 year, 2 years, and 5 years will be will be derived from the Humeral Head Centeredness assessment using the following definitions, from Iannotti and Norris et al.: 0. Absent: Humeral Head Centeredness is ≤25%. 1. Present: Humeral Head Centeredness is \>25%.

    Time frame: Day 0, 1 year, 2 years, and 5 years

  9. Radiographic Assessment - Device Condition: Anatomic

    Device Condition - Anatomic collected post-surgery at day 0, 1 year, 2 years, and 5 years will be graded in accordance with the following definitions: 0. Intact: No evidence of fracture, breakage, loosening, disassembly or migration of any of the components of the anatomic AETOS TSA. 1. Not Intact: Presence of fracture, breakage, loosening, disassembly or migration of one or more of the components of the anatomic AETOS TSA: * 1. Humeral Stem. * 2. Humeral Head. * 3. Glenoid. * 4. Post Extension.

    Time frame: Day 0, 1 year, 2 years, and 5 years

  10. Radiographic Assessment - Device Condition: Reverse

    Device Condition - Reverse collected post-surgery at day 0, 1 year, 2 years, and 5 years will be graded in accordance with the following definitions: 0. Intact: No evidence of fracture, breakage, loosening, disassembly or migration of any of the components of the reverse AETOS TSA. 1. Not Intact: Presence of fracture, breakage, loosening, disassembly or migration of one or more of the components of the reverse AETOS TSA: * 1. Humeral Stem. * 2. Reverse Liner. * 3. Glenosphere. * 4. Metal Glenoid. * 5. Peripheral Screws. * 6. Central Screw. * 7. Humeral Spacer. * 8. Post Extension.

    Time frame: Day 0, 1 year, 2 years, and 5 years

  11. American Shoulder and Elbow Score (ASES)

    The ASES instrument is composed of 2 sections containing participant self-reported and clinician assessments. The ASES score is a 0 to 100-point rating with a higher score indicating improvement in pain and function.

    Time frame: 6 months, 1 year, 2 years, and 5 years

  12. Constant Murley Score

    Constant-Murley Shoulder (CMS) scale assesses four aspects related to shoulder pathology; two subjective: pain and activities of daily living (ADL) and two objective: range of motion (ROM) and strength. The subjective components can receive up to 35 points and the objective 65, resulting in a possible maximum total score of 100 points (best function). Pain and ADL are answered by the subject; ROM and strength require a physical evaluation and are answered by the orthopaedic surgeon or the physiotherapist.

    Time frame: 6 months, 1 year, 2 years, and 5 years

  13. Simple Shoulder Test (SST)

    Series of 12 "yes" or "no" questions the patient answers about the function of the involved shoulder. The answer to these questions provides a standardized way of recording the function of a shoulder before and after treatment.

    Time frame: 6 months, 1 year, 2 years, and 5 years

  14. Single Assessment Numeric Evaluation (SANE)

    The SANE is a simple, single-question, patient-based shoulder function assessment tool: ''How would you rate your shoulder today as a percentage of normal (0% to 100% scale with 100% being normal)?''

    Time frame: 6 months, 1 year, 2 years, and 5 years

07

Study locations

5 of 5 sites recruiting
  • California Pacific Orthopedics
    San Francisco, California 94118, United States
    Recruiting
  • Western Orthopaedics
    Denver, Colorado 80210, United States
    Recruiting
  • Hughston Foundation
    Columbus, Georgia 31909, United States
    Recruiting
    • Cholly Minton · Contactcminton@hughston.com · 706-494-3330
    • Brent Ponce · Principal investigator
  • Center for Orthopedics and Neurosurgical Care
    Bend, Oregon 97701, United States
    Recruiting
  • Rothman Institute
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
    • Brooke Olin · Contact267-516-9393
    • Matthew Ramsey, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Aug 2027, 41 months after the start.

Of 82 industry-sponsored observational studies under Osteoarthritis, half reached primary completion within 93 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 184. This study's planned 41 months is below that.

Counting every sponsor, half of 228 studies reached it within 57 months; a quarter within 21 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2024
First posted
Mar 20, 2024
StartActual
Mar 5, 2024
Primary completionEst.
Aug 30, 2027
CompletionEst.
Aug 30, 2030
Last update
May 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06319911
Responsible party
Sponsor
First posted
Mar 20, 2024
Start date
Mar 5, 2024
Primary completion
Aug 30, 2027 (estimated)
Completion
Aug 30, 2030 (estimated)
Last update
May 7, 2024

Study contacts

Tammy Clark, MPH
Contact
tammy.clark@smith-nephew.com
3512269585
Karlie Morgan
Contact
karlie.morgan@smith-nephew.com
5124967507
Kolja Boese
study director · Smith & Nephew, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion